Article Information
History
- November 7, 2022.
Article Versions
- Version 1 (April 5, 2022 - 12:01).
- Version 2 (April 30, 2022 - 13:08).
- Version 3 (July 27, 2022 - 18:43).
- You are viewing Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Nancy Alnassar1,
- Malgorzata Borczyk2,
- Georgia Tsagkogeorga3,4,
- Michal Korostynski2,
- Namshik Han3,5 and
- Dariusz C Górecki1,*
- 1School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK
- 2Laboratory of Pharmacogenomics, Maj Institute of Pharmacology PAS, Krakow, Poland
- 3Milner Therapeutics Institute, University of Cambridge, Cambridge, UK
- 4STORM Therapeutics Ltd, Babraham Research Campus, Cambridge, UK
- 5Cambridge Centre for AI in Medicine, University of Cambridge, Cambridge, UK
- ↵*to whom correspondence should be addressed, email: darek.gorecki{at}port.ac.uk